Company profile
Universal Ibogaine Inc.
OTC: IBOGF · Healthcare · Biotechnology
Canadian filerHQ Calgary, ABReports USD
#882 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 26
v0.1 · 5/100 weight · pillars only
↑ operating margin, Piotroski F · ↓ listing tenure, return on equity
Methodology →Revenue TTM
$1.1M
Rev growth YoY (TTM)
+49.7%
Net income (FY)
-$8.3M
Employees
7
as of 2026-08-23
Market cap
$7.2M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$843.7k1.1M CAD2022
Net income-$8.3M-10.5M CAD2022
Operating income$391.7k497.2k CAD2022
Total assets$4.9M6.3M CAD2022
Liabilities$1.9M2.4M CAD2022
Equity$3.1M3.9M CAD2022
Revenue trend
FY2018 – FY2022 · USD
FY18
FY19
FY20
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Universal Ibogaine Inc.’s revenue?
Universal Ibogaine Inc. booked $843.7k in FY2022 revenue — among the slowest-growing Healthcare companies we track, at a -980.2% net margin.
Peers · Healthcare
Profile Solutions, Inc.——IGC Pharma, Inc.45DRallybio Corporation47DAdvantis Corp.——Imagenetix, Inc.——Catheter Precision, Inc.39DKey facts
CEONicholas Peter Karos
SectorHealthcare
IndustryBiotechnology
HeadquartersCalgary, AB
ExchangeOTC: IBOGF
Employees7
IPO date2022-03-01
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.